000 Today's Stocks

[DorseyE]

Stock ready to move:
MSN Money Opinion:
http://moneycentral.msn.com/investor/invsub/analyst/recomnd.asp?Symbol=AVNR
http://moneycentral.msn.com/investor/srs/srsmain.asp?Symbol=AVNR

Five Analyst opinions for the next 52 wks.
High Target: $56.00
Low Target: $23.00
Median Target: $30.00
http://finance.yahoo.com/q/ao?s=AVNR

Cramer's take on AVNR:
http://www.thestreet.com/_yahoo/funds/madmoneywrap/10278701_2.html
Avanir's Promising Prospect

Avanir Pharmaceuticals (AVNR:Nasdaq - commentary - research - Cramer's Take) just listed on the Nasdaq (it used to trade on the Amex), and, Cramer said, it's time to buy the stock because the Food and Drug Administration has given some of its formulations priority status.

The only thing better than a company having pull with the government is a company that has products so good that it doesn't need pull with the government, he said.

One of these treatments is Neurodex, which treats pseudobulbar affect (PBA). This condition, which often afflicts people with Lou Gehrig's disease and multiple sclerosis, causes uncontrollable bouts of laughter or tears. The FDA has given Neurodex fast track status, and Cramer said that it should be able to do $150 million in sales if it is approved.
http://biz.yahoo.com/ap/060404/avanir_neurodex.html?.v=1
Better still, he said that the treatment could also get "orphan drug status," giving it a seven-year monopoly in addition to patent protection.

The company is working with Novartis (NVS:NYSE ADR - commentary - research - Cramer's Take) on deals that could earn Avanir $200 million in milestone payments, and is also involved in deals with AstraZeneca (AZN:NYSE ADR - commentary - research - Cramer's Take).
http://www.b2i.us/profiles/investor/ResLibraryView.asp?ResLibraryID=13674&GoTopage=2&BzID=95...